Multiple Myeloma Clinical Trial
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, administered intravenously (IV) in monotherapy (Arm 1) or combination with BMS-986405 (Arm 2), to determine the maximum tolerated dose (MTD) of CC-99712 guided by a Bayesian logistic regression model (BLRM). A modified accelerated titration design will also be used for Arm 1 and Arm 2. The MTD may be established separately for CC-99712 administered at Q3W and/ or Q4W schedules. The expansion part (Part B) will further evaluate the safety and efficacy of CC-99712 in monotherapy (Arm 1) or combination (Arm 2) administered at or below the MTD in selected expansion cohorts in order to determine the RP2D. One or more doses or dosing regimens may be selected for cohort expansion. All participants will be treated until confirmed disease progression per IMWG criteria, unacceptable toxicity, or participants//Investigator decision to withdraw.
Participants must satisfy the following criteria to be enrolled in the study:
Participant is â‰¥ 18 years of age at the time of signing the ICF.
Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease
Participant must have measurable disease.
Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Participant has symptomatic central nervous system involvement of MM.
Participant had a prior autologous stem cell transplant â‰¤ 3 months prior to starting CC-99712.
Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning â‰¤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.
Subject is a pregnant or lactating female.
Subject has known human immunodeficiency virus (HIV) infection.
Subject has active hepatitis B or C (HBV/HCV) infection.
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
La Jolla California, 92093, United States
Sarasota Florida, 34232, United States
Buffalo New York, 14263, United States
New York New York, 10029, United States
Portland Oregon, 97239, United States
Dallas Texas, 75390, United States
Seattle Washington, 98104, United States
Toronto Ontario, M5G 2, Canada
Montreal Quebec, H1T 2, Canada
Marseille Cedex 9 , 13273, France
Montpellier CEDEX 5 , 34295, France
Paris , 75571, France
Pierre BÃ©nite , 69495, France
Bologna , 40138, Italy
Barcelona , 08036, Spain
Madrid , 28041, Spain
Salamanca , 37007, Spain
Sevillla , 41013, Spain
Valencia , 46026, Spain
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.